![]() |
|
|
Vol. 16, Issue 11, 5061-5069, November 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Immunology, Weizmann Institute of Science, 76100 Rehovot, Israel
Submitted April 20, 2005;
Revised August 9, 2005;
Accepted August 10, 2005
Monitoring Editor: Peter Walter
Quite a few regulatory proteins, including transcription factors, are normally maintained in a dormant state to be activated after internal or environmental cues. Recently, a novel strategy, requiring proteolytic cleavage, was described for the mobilization of dormant transcription factors. These transcription factors are initially synthesized in an inactive form, whereas "nesting" in integral membrane precursor proteins. After a cleavage event, these new active factors are released from the membrane and can migrate into the nucleus to drive regulated gene transcription. This mechanism, regulated intramembrane proteolysis (RIP), controls diverse biological processes in prokaryotes and eukaryotes in response to a variety of signals. The MHC class II chaperone, CD74 (invariant chain, Ii), was previously shown to function as a signaling molecule in several pathways. Recently, we demonstrated that after intramembranal cleavage, the CD74 cytosolic fragment (CD74-ICD) is released and induces activation of transcription mediated by the NF-
B p65/RelA homodimer and the B-cell-enriched coactivator, TAFII105. Here, we add CD74 to the growing family of RIP-processed proteins. Our studies show that CD74 ectodomain must be processed in the endocytic compartments to allow its intramembrane cleavage that liberates CD74 intracellular domain (CD74-ICD). We demonstrate that CD74-ICD translocates to the nucleus and induces the activation of the p65 member of NF-
B in this compartment.
* These authors contributed equally to this work.
Address correspondence to: Idit Shachar (idit.shachar{at}weizmann.ac.il).
This article has been cited by other articles:
![]() |
J. L. Martin-Ventura, J. Madrigal-Matute, B. Munoz-Garcia, L. M. Blanco-Colio, M. Van Oostrom, G. Zalba, A. Fortuno, C. Gomez-Guerrero, L. Ortega, A. Ortiz, et al. Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells Cardiovasc Res, June 4, 2009; (2009) cvp141v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Stein, M. R. Smith, S. Chen, M. Zalath, and D. M. Goldenberg Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines Clin. Cancer Res., April 15, 2009; 15(8): 2808 - 2817. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gelin, I. Sloma, D. Charron, and N. Mooney Regulation of MHC II and CD1 antigen presentation: from ubiquity to security J. Leukoc. Biol., February 1, 2009; 85(2): 215 - 224. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Sanchez-Nino, A. B. Sanz, P. Ihalmo, M. Lassila, H. Holthofer, S. Mezzano, C. Aros, P.-H. Groop, M. A. Saleem, P. W. Mathieson, et al. The MIF Receptor CD74 in Diabetic Podocyte Injury J. Am. Soc. Nephrol., February 1, 2009; 20(2): 353 - 362. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Elzinga, C. Twomey, J. C. Powell, F. Harte, and J. V. McCarthy Interleukin-1 Receptor Type 1 Is a Substrate for {gamma}-Secretase-dependent Regulated Intramembrane Proteolysis J. Biol. Chem., January 16, 2009; 284(3): 1394 - 1409. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Szaszak, H.-D. Chen, H.-C. Chen, A. Baukal, L. Hunyady, and K. J Catt Identification of the invariant chain (CD74) as an angiotensin AGTR1-interacting protein J. Endocrinol., November 1, 2008; 199(2): 165 - 176. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ye, X. Liu, S. N. Rout, Z. Li, Y. Yan, L. Lu, T. Kamala, N. K. Nanda, W. Song, S. K. Samal, et al. The MHC Class II-Associated Invariant Chain Interacts with the Neonatal Fc{gamma} Receptor and Modulates Its Trafficking to Endosomal/Lysosomal Compartments J. Immunol., August 15, 2008; 181(4): 2572 - 2585. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Gore, D. Starlets, N. Maharshak, S. Becker-Herman, U. Kaneyuki, L. Leng, R. Bucala, and I. Shachar Macrophage Migration Inhibitory Factor Induces B Cell Survival by Activation of a CD74-CD44 Receptor Complex J. Biol. Chem., February 1, 2008; 283(5): 2784 - 2792. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Huang, D. T. Cai, R. Y. R. Chua, D. M. Kemeny, and S. H. Wong Nitric-oxide Synthase 2 Interacts with CD74 and Inhibits Its Cleavage by Caspase during Dendritic Cell Development J. Biol. Chem., January 18, 2008; 283(3): 1713 - 1722. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hussain, C. Wesley, M. Khalid, A. Chaudhry, and S. Jameel Human Immunodeficiency Virus Type 1 Vpu Protein Interacts with CD74 and Modulates Major Histocompatibility Complex Class II Presentation J. Virol., January 15, 2008; 82(2): 893 - 902. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Lantner, D. Starlets, Y. Gore, L. Flaishon, A. Yamit-Hezi, R. Dikstein, L. Leng, R. Bucala, Y. Machluf, M. Oren, et al. CD74 induces TAp63 expression leading to B-cell survival Blood, December 15, 2007; 110(13): 4303 - 4311. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Stein, M. J. Mattes, T. M. Cardillo, H. J. Hansen, C.-H. Chang, J. Burton, S. Govindan, and D. M. Goldenberg CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms Clin. Cancer Res., September 15, 2007; 13(18): 5556s - 5563s. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Binsky, M. Haran, D. Starlets, Y. Gore, F. Lantner, N. Harpaz, L. Leng, D. M. Goldenberg, L. Shvidel, A. Berrebi, et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival PNAS, August 14, 2007; 104(33): 13408 - 13413. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Starlets, Y. Gore, I. Binsky, M. Haran, N. Harpaz, L. Shvidel, S. Becker-Herman, A. Berrebi, and I. Shachar Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival Blood, June 15, 2006; 107(12): 4807 - 4816. [Abstract] [Full Text] [PDF] |
||||